Broader Medicare Part D Coverage For Off-Label Drug Use Gets Boost From Court Decision
This article was originally published in The Pink Sheet Daily
New York federal court decides three-year-old case brought by the Medicare Rights Center against the federal government.
You may also be interested in...
The Medicare Rights Center is continuing a lawsuit seeking to expand coverage for off-label indications under the Medicare Part D prescription drug benefit after helping a beneficiary gain coverage of a drug to treat ovarian cancer
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.